The purpose of this study is to determine the optimal dosage of the clinical trial which is evaluating the antihypertensive efficacy and the safety of OJP-2028 tablets in patients with the uncomplicated essential hypertension.
Evaluating the antihypertensive efficacy and the safety of OJP-2028 tablets in patients with the uncomplicated essential hypertension.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
120
Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Average SiDBP Differences of test group vs control group per each dosage by comparison with the baseline.
Time frame: 8 weeks
Average SiSBP Differences of each group by comparison with the baseline.
Time frame: 8 weeks
Responder rate of each group by comparison with the baseline.
Time frame: 8 weeks
Average SiDBP and SiSBP Differences of each group by comparison with the baseline.
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.